Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
Historique:
received: 26 08 2018
revised: 07 01 2019
accepted: 08 01 2019
pubmed: 5 2 2019
medline: 18 8 2020
entrez: 5 2 2019
Statut: ppublish

Résumé

In the warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, variable phenotypic expression may delay diagnosis. Panleukopenia, malignancy, and chronic lung disease all affect morbidity and mortality risks. Routinely used treatments include immunoglobulins, granulocyte-colony stimulating factor (G-CSF), and antibiotics; recent trials with a target C-X-C chemokine receptor type 4 (CXCR4) antagonist show promising results. We sought to characterize the largest cohort of patients with WHIM and evaluate their diagnostic and therapeutic management. Data were collected from an international cohort of 18 patients with CXCR4 mutations. The clinical features manifested at 2.2 ± 2.6 years of age, whereas the disease diagnosis was delayed until 12.5 ± 10.4 years of age. Patients with WHIM commonly presented with a severe bacterial infection (78%). Pneumonia recurrence was observed in 61% of patients and was complicated with bronchiectasis in 27%. Skin warts were observed in 61% of patients at a mean age of 11 years, whereas human papilloma virus (HPV)-related malignancies manifested in 16% of patients. All the patients had severe neutropenia (195 ± 102 cells/mm The WHIM syndrome onsets early in life and should be suspected in patients with chronic neutropenia. Patients with WHIM need careful monitoring and timely intervention for complications, mainly lung disease and HPV-related malignancies. We suggest that immunoglobulin therapy should be promptly considered to control the frequency of bacterial infections and prevent chronic lung damage.

Sections du résumé

BACKGROUND
In the warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, variable phenotypic expression may delay diagnosis. Panleukopenia, malignancy, and chronic lung disease all affect morbidity and mortality risks. Routinely used treatments include immunoglobulins, granulocyte-colony stimulating factor (G-CSF), and antibiotics; recent trials with a target C-X-C chemokine receptor type 4 (CXCR4) antagonist show promising results.
OBJECTIVE
We sought to characterize the largest cohort of patients with WHIM and evaluate their diagnostic and therapeutic management.
METHODS
Data were collected from an international cohort of 18 patients with CXCR4 mutations.
RESULTS
The clinical features manifested at 2.2 ± 2.6 years of age, whereas the disease diagnosis was delayed until 12.5 ± 10.4 years of age. Patients with WHIM commonly presented with a severe bacterial infection (78%). Pneumonia recurrence was observed in 61% of patients and was complicated with bronchiectasis in 27%. Skin warts were observed in 61% of patients at a mean age of 11 years, whereas human papilloma virus (HPV)-related malignancies manifested in 16% of patients. All the patients had severe neutropenia (195 ± 102 cells/mm
CONCLUSIONS
The WHIM syndrome onsets early in life and should be suspected in patients with chronic neutropenia. Patients with WHIM need careful monitoring and timely intervention for complications, mainly lung disease and HPV-related malignancies. We suggest that immunoglobulin therapy should be promptly considered to control the frequency of bacterial infections and prevent chronic lung damage.

Identifiants

pubmed: 30716504
pii: S2213-2198(19)30117-5
doi: 10.1016/j.jaip.2019.01.045
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antineoplastic Agents 0
CXCR4 protein, human 0
Codon, Nonsense 0
Keratolytic Agents 0
Receptors, CXCR4 0
Retinoids 0
Granulocyte Colony-Stimulating Factor 143011-72-7
Salicylic Acid O414PZ4LPZ
Imiquimod P1QW714R7M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1568-1577

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Laura Dotta (L)

Department of Pediatrics, Institute of Molecular Medicine "Angelo Nocivelli," Asst Spedali Civili of Brescia, Brescia, Italy. Electronic address: lauradotta@icloud.com.

Lucia Dora Notarangelo (LD)

Pediatric Hematology Oncology Unit, Asst Spedali Civili of Brescia, Brescia, Italy.

Daniele Moratto (D)

Institute of Molecular Medicine "Angelo Nocivelli," University of Brescia, Asst Spedali Civili of Brescia, Brescia, Italy.

Rajesh Kumar (R)

Institute of Molecular Medicine "Angelo Nocivelli," University of Brescia, Asst Spedali Civili of Brescia, Brescia, Italy.

Fulvio Porta (F)

Pediatric Hematology Oncology Unit, Asst Spedali Civili of Brescia, Brescia, Italy.

Annarosa Soresina (A)

Department of Pediatrics, Institute of Molecular Medicine "Angelo Nocivelli," Asst Spedali Civili of Brescia, Brescia, Italy.

Vassilios Lougaris (V)

Department of Pediatrics, Institute of Molecular Medicine "Angelo Nocivelli," University of Brescia, Asst Spedali Civili of Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, Institute of Molecular Medicine "Angelo Nocivelli," University of Brescia, Asst Spedali Civili of Brescia, Brescia, Italy.

Alessandro Plebani (A)

Department of Pediatrics, Institute of Molecular Medicine "Angelo Nocivelli," University of Brescia, Asst Spedali Civili of Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, Institute of Molecular Medicine "Angelo Nocivelli," University of Brescia, Asst Spedali Civili of Brescia, Brescia, Italy.

C I Edvard Smith (CIE)

Clinical Research Center, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden.

Anna-Carin Norlin (AC)

Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Immunology and Transfusion Medicine, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.

Andrea Cecilia Gòmez Raccio (AC)

Immunology Unit, Children's Hospital Ricardo Gutierrez, Buenos Aires, Argentina.

Eva Bubanska (E)

Department of Pediatric Oncology and Hematology, University Children's Hospital, Banska Bystrica, Slovakia.

Patrizia Bertolini (P)

Pediatric Hematology Oncology Unit, Azienda Ospedaliero Universitaria of Parma, Parma, Italy.

Giovanni Amendola (G)

Department of Pediatrics, Nocera Inferiore Hospital, Salerno, Italy.

Marcella Visentini (M)

Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.

Massimo Fiorilli (M)

Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.

Aldo Venuti (A)

HPV-Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Raffaele Badolato (R)

Department of Pediatrics, Institute of Molecular Medicine "Angelo Nocivelli," University of Brescia, Asst Spedali Civili of Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, Institute of Molecular Medicine "Angelo Nocivelli," University of Brescia, Asst Spedali Civili of Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH